ロード中...
Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis
PURPOSE: Although oral prednisolone is the first-line treatment for preventing recurrent optic neuritis (ON) after the completion of acute-phase treatment, especially anti-aquaporin 4 (AQP4) antibody-positive ON, and anti-myelin oligodendrocyte glycoprotein (MOG) antibody-positive ON, some patients...
保存先:
| 出版年: | J Ophthalmol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Hindawi
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7883711/ https://ncbi.nlm.nih.gov/pubmed/33628473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/8871146 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|